Citation: | BI Yan, LU Bin, Organ Transplantation and Rehabilitation Committee of Chinese Medical Association of Rehabilitation. Expert consensus on diabetes mellitus after solid organ transplantation in adults[J]. ORGAN TRANSPLANTATION, 2023, 14(5): 623-642. doi: 10.3969/j.issn.1674-7445.2023110 |
[1] |
JENSSEN T, HARTMANN A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3): 172-188. DOI: 10.1038/s41574-018-0137-7.
|
[2] |
DAVIDSON J, WILKINSON A, DANTAL J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003[J]. Transplantation, 2003, 75(10 Suppl): SS3- SS24. DOI: 10.1097/01.TP.0000069952.49242.3E.
|
[3] |
SHARIF A, HECKING M, DE VRIES AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions[J]. Am J Transplant, 2014, 14(9): 1992-2000. DOI: 10.1111/ajt.12850.
|
[4] |
PORRINI EL, DÍAZ JM, MORESO F, et al. Clinical evolution of post-transplant diabetes mellitus[J]. Nephrol Dial Transplant, 2016, 31(3): 495-505. DOI: 10.1093/ndt/gfv368.
|
[5] |
MOON JI, BARBEITO R, FARADJI RN, et al. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up[J]. Transplantation, 2006, 82(12): 1625-1628. DOI: 10.1097/01.tp.0000250361.60415.96.
|
[6] |
BHAT M, USMANI SE, AZHIE A, et al. Metabolic consequences of solid organ transplantation[J]. Endocr Rev, 2021, 42(2): 171-197. DOI: 10.1210/endrev/bnaa030.
|
[7] |
LIANG J, LV C, CHEN M, et al. Effects of preoperative hepatitis B virus infection, hepatitis C virus infection, and coinfection on the development of new-onset diabetes after kidney transplantation[J]. J Diabetes, 2019, 11(5): 370-378. DOI: 10.1111/1753-0407.12853.
|
[8] |
XU J, XU L, WEI X, et al. Incidence and risk factors of posttransplantation diabetes mellitus in living donor kidney transplantation: a single-center retrospective study in China[J]. Transplant Proc, 2018, 50(10): 3381-3385. DOI: 10.1016/j.transproceed.2018.08.007.
|
[9] |
陈敏灵, 张尧, 于明香, 等. 肾移植术后糖尿病的发病及其危险因素分析[J]. 中华内分泌代谢杂志, 2013, 29(9): 750-755. DOI: 10.3760/cma.j.issn.1000-6699.2013.09.004.
CHEN ML, ZHANG Y, YU MX, et al. An analysis on the prevalence and risk factors of post-transplant diabetes mellitus after renal transplantation[J]. Chin J Endocrinol Metab, 2013, 29(9): 750-755. DOI: 10.3760/cma.j.issn.1000-6699.2013.09.004.
|
[10] |
LING Q, XU X, XIE H, et al. New-onset diabetes after liver transplantation: a national report from China Liver Transplant Registry[J]. Liver Int, 2016, 36(5): 705-712. DOI: 10.1111/liv.13042.
|
[11] |
ZHAO T, ZHAO Y, ZONG A, et al. Association of body mass index and fasting plasma glucose concentration with post-transplantation diabetes mellitus in Chinese heart transplant recipients[J]. J Int Med Res, 2020, 48(3): 300060520910629. DOI: 10.1177/0300060520910629.
|
[12] |
章保勇, 胡盛寿, 黄洁, 等. 心脏移植受者移植后新发糖尿病的危险因素分析[J]. 中华器官移植杂志, 2014, 35(4): 221-224. DOI: 10.3760/cma.j.issn.0254-1785.2014.04.007.
ZHANG BY, HU SS, HUANG J, et al. Incidence and risk factors of post-transplant diabetes mellitus in heart recipients[J]. Chin J Organ Transplant, 2014, 35(4): 221-224. DOI: 10.3760/cma.j.issn.0254-1785.2014.04.007.
|
[13] |
EIDE IA, HALDEN TA, HARTMANN A, et al. Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria[J]. Transpl Int, 2016, 29(5): 568-578. DOI: 10.1111/tri.12757.
|
[14] |
HACKMAN KL, SNELL GI, BACH LA. Poor glycemic control is associated with decreased survival in lung transplant recipients[J]. Transplantation, 2017, 101(9): 2200-2206. DOI: 10.1097/TP.0000000000001555.
|
[15] |
D'AVOLA D, CUERVAS-MONS V, MARTÍ J, et al. Cardiovascular morbidity and mortality after liver transplantation: the protective role of mycophenolate mofetil[J]. Liver Transpl, 2017, 23(4): 498-509. DOI: 10.1002/lt.24738.
|
[16] |
ROCCARO GA, GOLDBERG DS, HWANG WT, et al. Sustained posttransplantation diabetes is associated with long-term major cardiovascular events following liver transplantation[J]. Am J Transplant, 2018, 18(1): 207-215. DOI: 10.1111/ajt.14401.
|
[17] |
SHIVASWAMY V, BOERNER B, LARSEN J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes[J]. Endocr Rev, 2016, 37(1): 37-61. DOI: 10.1210/er.2015-1084.
|
[18] |
FENG KY, HENRICKSEN EJ, WAYDA B, et al. Impact of diabetes mellitus on clinical outcomes after heart transplantation[J]. Clin Transplant, 2021, 35(11): e14460. DOI: 10.1111/ctr.1446.
|
[19] |
KIM HJ, JUNG SH, KIM JJ, et al. New-onset diabetes mellitus after heart transplantation- incidence, risk factors and impact on clinical outcome[J]. Circ J, 2017, 81(6): 806-814. DOI: 10.1253/circj.CJ-16-0963.
|
[20] |
VEST AR, CHERIKH WS, NOREEN SM, et al. New-onset diabetes mellitus after adult heart transplantation and the risk of renal dysfunction or mortality[J]. Transplantation, 2022, 106(1): 178-187. DOI: 10.1097/TP.0000000000003647.
|
[21] |
CHO MS, CHOI HI, KIM IO, et al. The clinical course and outcomes of post-transplantation diabetes mellitus after heart transplantation[J]. J Korean Med Sci, 2012, 27(12): 1460-1467. DOI: 10.3346/jkms.2012.27.12.1460.
|
[22] |
MORO JA, MARTÍNEZ-DOLZ L, ALMENAR L, et al. Impact of diabetes mellitus on heart transplant recipients[J]. Rev Esp Cardiol, 2006, 59(10): 1033-1037. DOI: 10.1157/13093980.
|
[23] |
KIROV H, MOSCHOVAS A, CALDONAZO T, et al. Diabetes is an independent risk factor for cancer after heart and/or lung transplantation[J]. J Clin Med, 2022, 11(14): 4127. DOI: 10.3390/jcm11144127.
|
[24] |
HACKMAN KL, BAILEY MJ, SNELL GI, et al. Diabetes is a major risk factor for mortality after lung transplantation[J]. Am J Transplant, 2014, 14(2): 438-445. DOI: 10.1111/ajt.12561.
|
[25] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.
Branch of Diabetes of Chinese Medical Association. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition) [J]. Chin J Diabetes, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.
|
[26] |
CHEUNGPASITPORN W, THONGPRAYOON C, VIJAYVARGIYA P, et al. The risk for new-onset diabetes mellitus after kidney transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis[J]. Can J Diabetes, 2016, 40(6): 521-528. DOI: 10.1016/j.jcjd.2016.03.001.
|
[27] |
SHAH T, KASRAVI A, HUANG E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation[J]. Transplantation, 2006, 82(12): 1673-1676. DOI: 10.1097/01.tp.0000250756.66348.9a.
|
[28] |
FABRIZI F, MARTIN P, DIXIT V, et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies[J]. Am J Transplant, 2005, 5(10): 2433-2440. DOI: 10.1111/j.1600-6143.2005.01040.x.
|
[29] |
PRASAD N, GURJER D, BHADAURIA D, et al. Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients? [J]. Nephrology (Carlton), 2014, 19(4): 244-250. DOI: 10.1111/nep.12209.
|
[30] |
BAID S, COSIMI AB, FARRELL ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality[J]. Transplantation, 2001, 72(6): 1066-1072. DOI: 10.1097/00007890-200109270-00015.
|
[31] |
CHEN T, JIA H, LI J, et al. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies[J]. Transpl Int, 2009, 22(4): 408-415. DOI: 10.1111/j.1432-2277.2008.00804.x.
|
[32] |
SABHARWAL S, DELGADO-BORREGO A, CHUNG RT. Extrahepatic hepatitis C virus after transplantation: diabetes and renal dysfunction[J]. Liver Transpl, 2008, 14(Suppl 2): S51-S57. DOI: 10.1002/lt.21613.
|
[33] |
YOUNOSSI Z, STEPANOVA M, SAAB S, et al. The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17 000 HCV-infected transplant recipients[J]. Aliment Pharmacol Ther, 2015, 41(2): 209-217. DOI: 10.1111/apt.13027.
|
[34] |
HANDISURYA A, KERSCHER C, TURA A, et al. Conversion from tacrolimus to cyclosporine a improves glucose tolerance in HCV-positive renal transplant recipients[J]. PLoS One, 2016, 11(1): e0145319. DOI: 10.1371/journal.pone.0145319.
|
[35] |
SALIBA F, LAKEHAL M, PAGEAUX GP, et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study[J]. Liver Transpl, 2007, 13(1): 136-144. DOI: 10.1002/lt.21010.
|
[36] |
TOSHIMA T, YOSHIZUMI T, INOKUCHI S, et al. Risk factors for the metabolic syndrome components of hypertension, diabetes mellitus, and dyslipidemia after living donor liver transplantation[J]. HPB (Oxford), 2020, 22(4): 511-520. DOI: 10.1016/j.hpb.2019.08.008.
|
[37] |
XUE M, LV C, CHEN X, et al. Donor liver steatosis: a risk factor for early new-onset diabetes after liver transplantation[J]. J Diabetes Investig, 2017, 8(2): 181-187. DOI: 10.1111/jdi.12560.
|
[38] |
SHAKED A, LOZA BL, VAN LOON E, et al. Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes[J]. Nat Med, 2022, 28(5): 999-1005. DOI: 10.1038/s41591-022-01758-7.
|
[39] |
HUSCHER D, THIELE K, GROMNICA-IHLE E, et al. Dose-related patterns of glucocorticoid-induced side effects[J]. Ann Rheum Dis, 2009, 68(7): 1119-1124. DOI: 10.1136/ard.2008.092163.
|
[40] |
QI D, RODRIGUES B. Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism[J]. Am J Physiol Endocrinol Metab, 2007, 292(3): E654-E667. DOI: 10.1152/ajpendo.00453.2006.
|
[41] |
MIDTVEDT K, HJELMESAETH J, HARTMANN A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal[J]. J Am Soc Nephrol, 2004, 15(12): 3233-3239. DOI: 10.1097/01.ASN.0000145435.80005.1E.
|
[42] |
MOURAD G, GLYDA M, ALBANO L, et al. Incidence of posttransplantation diabetes mellitus in de novo kidney transplant recipients receiving prolonged-release tacrolimus-based immunosuppression with 2 different corticosteroid minimization strategies: ADVANCE, a randomized controlled trial[J]. Transplantation, 2017, 101(8): 1924-1934. DOI: 10.1097/TP.0000000000001453.
|
[43] |
CHAKKERA HA, KUDVA Y, KAPLAN B. Calcineurin inhibitors: pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus[J]. Clin Pharmacol Ther, 2017, 101(1): 114-120. DOI: 10.1002/cpt.546.
|
[44] |
PEREIRA MJ, PALMING J, RIZELL M, et al. Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents[J]. J Clin Endocrinol Metab, 2014, 99(10): E1885-E1894. DOI: 10.1210/jc.2014-1266.
|
[45] |
VINCENTI F, FRIMAN S, SCHEUERMANN E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus[J]. Am J Transplant, 2007, 7(6): 1506-1514. DOI: 10.1111/j.1600-6143.2007.01749.x.
|
[46] |
TORRES A, HERNÁNDEZ D, MORESO F, et al. Randomized controlled trial assessing the impact of tacrolimus versus cyclosporine on the incidence of posttransplant diabetes mellitus[J]. Kidney Int Rep, 2018, 3(6): 1304-1315. DOI: 10.1016/j.ekir.2018.07.009.
|
[47] |
WISSING KM, ABRAMOWICZ D, WEEKERS L, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation[J]. Am J Transplant, 2018, 18(7): 1726-1734. DOI: 10.1111/ajt.14665.
|
[48] |
LIU J, LIU D, LI J, et al. Efficacy and safety of everolimus for maintenance immunosuppression of kidney transplantation: a meta-analysis of randomized controlled trials[J]. PLoS One, 2017, 12(1): e0170246. DOI: 10.1371/journal.pone.0170246.
|
[49] |
JONES-HUGHES T, SNOWSILL T, HAASOVA M, et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model[J]. Health Technol Assess, 2016, 20(62): 1-594. DOI: 10.3310/hta20620.
|
[50] |
CREPIN T, CARRON C, ROUBIOU C, et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients[J]. Am J Transplant, 2015, 15(4): 1028-1038. DOI: 10.1111/ajt.13092.
|
[51] |
BAKER D, HERROD SS, ALVAREZ-GONZALEZ C, et al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab[J]. JAMA Neurol, 2017, 74(8): 961-969. DOI: 10.1001/jamaneurol.2017.0676.
|
[52] |
ZHENG J, SONG W. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: a systematic review and meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2017, 96(28): e7151. DOI: 10.1097/MD.0000000000007151.
|
[53] |
SETOGUCHI R, HORI S, TAKAHASHI T, et al. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization[J]. J Exp Med, 2005, 201(5): 723-735. DOI: 10.1084/jem.20041982.
|
[54] |
AASEBØ W, MIDTVEDT K, VALDERHAUG TG, et al. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab[J]. Nephrol Dial Transplant, 2010, 25(4): 1289-1293. DOI: 10.1093/ndt/gfp617.
|
[55] |
AXELROD DA, CHEUNGPASITPORN W, BUNNAPRADIST S, et al. Posttransplant diabetes mellitus and immunosuppression selection in older and obese kidney recipients[J]. Kidney Med, 2021, 4(1): 100377. DOI: 10.1016/j.xkme.2021.08.012.
|
[56] |
SALIBA F, ROSTAING L, GUGENHEIM J, et al. Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: a randomized, multicenter study[J]. Transplantation, 2016, 100(8): 1705-1713. DOI: 10.1097/TP.0000000000001228.
|
[57] |
SCHWEER T, GWINNER W, SCHEFFNER I, et al. High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation[J]. Clin Transplant, 2014, 28(4): 512-519. DOI: 10.1111/ctr.12329.
|
[58] |
MONTORI VM, BASU A, ERWIN PJ, et al. Posttransplantation diabetes: a systematic review of the literature[J]. Diabetes Care, 2002, 25(3): 583-592. DOI: 10.2337/diacare.25.3.583.
|
[59] |
HJELMESAETH J, SAGEDAL S, HARTMANN A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation[J]. Diabetologia, 2004, 47(9): 1550-1556. DOI: 10.1007/s00125-004-1499-z.
|
[60] |
JIMÉNEZ-PÉREZ M, GONZÁLEZ-GRANDE R, OMONTE GUZMÁN E, et al. Metabolic complications in liver transplant recipients[J]. World J Gastroenterol, 2016, 22(28): 6416-6423. DOI: 10.3748/wjg.v22.i28.6416.
|
[61] |
LECRONIER M, TASHK P, TAMZALI Y, et al. Gut microbiota composition alterations are associated with the onset of diabetes in kidney transplant recipients[J]. PLoS One, 2020, 15(1): e0227373. DOI: 10.1371/journal.pone.0227373.
|
[62] |
FAUCHER Q, JARDOU M, BROSSIER C, et al. Is intestinal dysbiosis-associated with immunosuppressive therapy a key factor in the pathophysiology of post-transplant diabetes mellitus? [J]. Front Endocrinol (Lausanne), 2022, 13: 898878. DOI: 10.3389/fendo.2022.898878.
|
[63] |
VAN DER BURGH AC, MOES A, KIEBOOM BCT, et al. Serum magnesium, hepatocyte nuclear factor 1β genotype and post-transplant diabetes mellitus: a prospective study[J]. Nephrol Dial Transplant, 2020, 35(1): 176-183. DOI: 10.1093/ndt/gfz145.
|
[64] |
SCHWAIGER E, KRENN S, KURNIKOWSKI A, et al. Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation: a multicenter randomized trial[J]. J Am Soc Nephrol, 2021, 32(8): 2083-2098. DOI: 10.1681/ASN.2021010127.
|
[65] |
DOS SANTOS Q, HORNUM M, TERRONES-CAMPOS C, et al. Posttransplantation diabetes mellitus among solid organ recipients in a Danish cohort[J]. Transpl Int, 2022, 35: 10352. DOI: 10.3389/ti.2022.10352.
|
[66] |
IQBAL A, ZHOU K, KASHYAP SR, et al. Early post-renal transplant hyperglycemia[J]. J Clin Endocrinol Metab, 2022, 107(2): 549-562. DOI: 10.1210/clinem/dgab697.
|
[67] |
CONTE C, MAGGIORE U, CAPPELLI G, et al. Supporting physicians in the management of metabolic alterations in adult kidney transplant recipients: a comment on the joint position statement of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID) [J]. J Nephrol, 2020, 33(5): 887-893. DOI: 10.1007/s40620-020-00839-5.
|
[68] |
USSIF AM, ÅSBERG A, HALDEN TAS, et al. Validation of diagnostic utility of fasting plasma glucose and HbA1c in stable renal transplant recipients one year after transplantation[J]. BMC Nephrol, 2019, 20(1): 12. DOI: 10.1186/s12882-018-1171-3.
|
[69] |
YATES CJ, FOURLANOS S, COLMAN PG, et al. Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation[J]. Nephrol Dial Transplant, 2014, 29(3): 698-705. DOI: 10.1093/ndt/gft377.
|
[70] |
BURT MG, ROBERTS GW, AGUILAR-LOZA NR, et al. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD[J]. J Clin Endocrinol Metab, 2011, 96(6): 1789-1796. DOI: 10.1210/jc.2010-2729.
|
[71] |
AOUAD LJ, CLAYTON P, WYBURN KR, et al. Evolution of glycemic control and variability after kidney transplant[J]. Transplantation, 2018, 102(9): 1563-1568. DOI: 10.1097/TP.0000000000002155.
|
[72] |
YATES CJ, FOURLANOS S, COLMAN PG, et al. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin[J]. Transplantation, 2013, 96(8): 726-731. DOI: 10.1097/TP.0b013e3182a012f3.
|
[73] |
L. 凯萨琳·马汉. Krause营养诊疗学[M]. 杜寿玢, 陈伟, 译, 13版. 北京: 人民卫生出版社, 2017.
|
[74] |
中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2021年版)[J]. 中华糖尿病杂志, 2021, 13(10): 936-948. DOI: 10.3760/cma.j.cn115791-20210810-00436.
Branch of Diabetes of Chinese Medical Association. Clinical application guideline for blood glucose monitoring in China (2021 edition) [J]. Chin J Diabetes, 2021, 13(10): 936-948. DOI: 10.3760/cma.j.cn115791-20210810-00436.
|
[75] |
CHOWDHURY TA, WAHBA M, MALLIK R, et al. Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation[J]. Diabet Med, 2021, 38(6): e14523. DOI: 10.1111/dme.14523.
|
[76] |
VON VISGER JR, GUNAY Y, ANDREONI KA, et al. The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression[J]. Clin Transplant, 2014, 28(8): 845-854. DOI: 10.1111/ctr.12389.
|
[77] |
VEST LS, KORAISHY FM, ZHANG Z, et al. Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: a retrospective analysis of integrated registry and pharmacy claims data[J]. Clin Transplant, 2018, 32(8): e13302. DOI: 10.1111/ctr.13302.
|
[78] |
RAM E, LAVEE J, TENENBAUM A, et al. Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation[J]. Cardiovasc Diabetol, 2019, 18(1): 118. DOI: 10.1186/s12933-019-0925-y.
|
[79] |
HAIDINGER M, WERZOWA J, HECKING M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial[J]. Am J Transplant, 2014, 14(1): 115-123. DOI: 10.1111/ajt.12518.
|
[80] |
GUELER I, MUELLER S, HELMSCHROTT M, et al. Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation[J]. Drug Des Devel Ther, 2013, 7: 297-303. DOI: 10.2147/DDDT.S43092.
|
[81] |
STRØM HALDEN TA, ÅSBERG A, VIK K, et al. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation[J]. Nephrol Dial Transplant, 2014, 29(4): 926-933. DOI: 10.1093/ndt/gft536.
|
[82] |
BOERNER BP, MILES CD, SHIVASWAMY V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation[J]. Int J Endocrinol, 2014: 617638. DOI: 10.1155/2014/617638.
|
[83] |
BAE J, LEE MJ, CHOE EY, et al. Effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study[J]. Endocrinol Metab (Seoul), 2016, 31(1): 161-167. DOI: 10.3803/EnM.2016.31.1.161.
|
[84] |
SOLIMAN AR, FATHY A, KHASHAB S, et al. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant[J]. Exp Clin Transplant, 2013, 11(6): 494-498. DOI: 10.6002/ect.2013.0018.
|
[85] |
GUARDADO-MENDOZA R, CÁZARES-SÁNCHEZ D, EVIA-VISCARRA ML, et al. Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: a comparative study[J]. Diabetes Res Clin Pract, 2019, 156: 107864. DOI: 10.1016/j.diabres.2019.107864.
|
[86] |
HAIDINGER M, ANTLANGER M, KOPECKY C, et al. Post-transplantation diabetes mellitus: evaluation of treatment strategies[J]. Clin Transplant, 2015, 29(5): 415-424. DOI: 10.1111/ctr.12541.
|
[87] |
TÜRK T, PIETRUCK F, DOLFF S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation[J]. Am J Transplant, 2006, 6(4): 842-846. DOI: 10.1111/j.1600-6143.2006.01250.x.
|
[88] |
KAJOSAARI LI, NIEMI M, NEUVONEN M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide[J]. Clin Pharmacol Ther, 2005, 78(4): 388-399. DOI: 10.1016/j.clpt.2005.07.005.
|
[89] |
LUTHER P, BALDWIN D JR. Pioglitazone in the management of diabetes mellitus after transplantation[J]. Am J Transplant, 2004, 4(12): 2135-2138. DOI: 10.1111/j.1600-6143.2004.00613.x.
|
[90] |
WERZOWA J, HECKING M, HAIDINGER M, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial[J]. Transplantation, 2013, 95(3): 456-462. DOI: 10.1097/TP.0b013e318276a20e.
|
[91] |
HEERSPINK HJ, PERKINS BA, FITCHETT DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications[J]. Circulation, 2016, 134(10): 752-772. DOI: 10.1161/CIRCULATIONAHA.116.021887.
|
[92] |
NEAL B, PERKOVIC V, MATTHEWS DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(21): 2099. DOI: 10.1056/NEJMc1712572.
|
[93] |
RAJASEKERAN H, KIM SJ, CARDELLA CJ, et al. Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series[J]. Diabetes Care, 2017, 40(7): e75-e76. DOI: 10.2337/dc17-0237.
|
[94] |
MAHLING M, SCHORK A, NADALIN S, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus[J]. Kidney Blood Press Res, 2019, 44(5): 984-992. DOI: 10.1159/000501854.
|
[95] |
SONG CC, BROWN A, WINSTEAD R, et al. Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients[J]. Endocrinol Diabetes Metab, 2020, 4(2): e00185. DOI: 10.1002/edm2.185.
|
[96] |
MUIR CA, GREENFIELD JR, MACDONALD PS. Empagliflozin in the management of diabetes mellitus after cardiac transplantation[J]. J Heart Lung Transplant, 2017, 36(8): 914-916. DOI: 10.1016/j.healun.2017.05.005.
|
[97] |
CEHIC MG, MUIR CA, GREENFIELD JR, et al. Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients[J]. Transplant Direct, 2019, 5(5): e450. DOI: 10.1097/TXD.0000000000000885.
|
[98] |
SCHWAIGER E, BURGHART L, SIGNORINI L, et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety[J]. Am J Transplant, 2019, 19(3): 907-919. DOI: 10.1111/ajt.15223.
|
[99] |
HALDEN TAS, KVITNE KE, MIDTVEDT K, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus[J]. Diabetes Care, 2019, 42(6): 1067-1074. DOI: 10.2337/dc19-0093.
|
[100] |
KRISTENSEN SL, RØRTH R, JHUND PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol, 2019, 7(10): 776-785. DOI: 10.1016/S2213-8587(19)30249-9.
|
[101] |
VANHOVE T, REMIJSEN Q, KUYPERS D, et al. Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus[J]. Transplant Rev (Orlando), 2017, 31(2): 69-77. DOI: 10.1016/j.trre.2016.09.001.
|
[102] |
SINGH P, TAUFEEQ M, PESAVENTO TE, et al. Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: a retrospective study[J]. Diabetes Obes Metab, 2020, 22(5): 879-884. DOI: 10.1111/dom.13964.
|
[103] |
HALDEN TA, EGELAND EJ, ÅSBERG A, et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes[J]. Diabetes Care, 2016, 39(4): 617-624. DOI: 10.2337/dc15-2383.
|
[104] |
LIOU JH, LIU YM, CHEN CH. Management of diabetes mellitus with glucagonlike peptide-1 agonist liraglutide in renal transplant recipients: a retrospective study[J]. Transplant Proc, 2018, 50(8): 2502-2505. DOI: 10.1016/j.transproceed.2018.03.087.
|
[105] |
SINGH P, PESAVENTO TE, WASHBURN K, et al. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients[J]. Diabetes Obes Metab, 2019, 21(4): 1061-1065. DOI: 10.1111/dom.13619.
|
[106] |
STEPHEN J, ANDERSON-HAAG TL, GUSTAFSON S, et al. Metformin use in kidney transplant recipients in the United States: an observational study[J]. Am J Nephrol, 2014, 40(6): 546-553. DOI: 10.1159/000370034.
|
[107] |
ALEKSIC S, EISENBERG R, TSOMOS E, et al. Glycemic management and clinical outcomes in underserved minority kidney transplant recipients with type 2 and posttransplantation diabetes: a single-center retrospective study[J]. Diabetes Res Clin Pract, 2020, 165: 108221. DOI: 10.1016/j.diabres.2020.108221.
|
[108] |
SANYAL D, BISWAS M, CHAUDHARI N. Long-term efficacy and safety of anti-hyperglycaemic agents in new-onset diabetes after transplant: results from outpatient-based 1-year follow-up and a brief review of treatment options[J]. Diabetes Metab Syndr, 2021, 15(1): 13-19. DOI: 10.1016/j.dsx.2020.11.019.
|
[109] |
VOYTOVICH MH, HAUKEREID C, HJELMESAETH J, et al. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients[J]. Clin Transplant, 2007, 21(2): 246-251. DOI: 10.1111/j.1399-0012.2006.00634.x.
|
[110] |
RAVEN LM, MUIR CA, KESSLER IGLESIAS C, et al. Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial[J]. BMJ Open, 2023, 13(3): e069641. DOI: 10.1136/bmjopen-2022-069641.
|
[111] |
DZIODZIO T, BIEBL M, ÖLLINGER R, et al. The role of bariatric surgery in abdominal organ transplantation-the next big challenge? [J]. Obes Surg, 2017, 27(10): 2696-2706. DOI: 10.1007/s11695-017-2854-8.
|
[112] |
HADJIEVANGELOU N, KULENDRAN M, MCGLONE ER, et al. Is bariatric surgery in patients following renal transplantation safe and effective? a best evidence topic[J]. Int J Surg, 2016, 28: 191-195. DOI: 10.1016/j.ijsu.2016.02.095.
|
[113] |
SCHINDEL H, WINKLER J, YEMINI R, et al. Survival benefit in bariatric surgery kidney recipients may be mediated through effects on kidney graft function and improvement of co-morbidities: a case-control study[J]. Surg Obes Relat Dis, 2019, 15(4): 621-627. DOI: 10.1016/j.soard.2019.01.034.
|
[114] |
HECKING M, HAIDINGER M, DÖLLER D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation[J]. J Am Soc Nephrol, 2012, 23(4): 739-749. DOI: 10.1681/ASN.2011080835.
|
[115] |
American Diabetes Association Professional Practice Committee. 16. Diabetes care in the hospital: standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S244-S253. DOI: 10.2337/dc22-S016.
|
[116] |
LO C, TOYAMA T, OSHIMA M, et al. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients[J]. Cochrane Database Syst Rev, 2020, 8(8): CD009966. DOI: 10.1002/14651858.CD009966.pub3.
|
[117] |
XIA M, YANG H, TONG X, et al. Risk factors for new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis[J]. J Diabetes Investig, 2021, 12(1): 109-122. DOI: 10.1111/jdi.13317.
|
[118] |
CAI R, WU M, XING Y. Pretransplant metabolic syndrome and its components predict post-transplantation diabetes mellitus in Chinese patients receiving a first renal transplant[J]. Ther Clin Risk Manag, 2019, 15: 497-503. DOI: 10.2147/TCRM.S190185.
|
[119] |
ADAMS LA, ARAUZ O, ANGUS PW, et al. Additive impact of pre-liver transplant metabolic factors on survival post-liver transplant[J]. J Gastroenterol Hepatol, 2016, 31(5): 1016-1024. DOI: 10.1111/jgh.13240.
|
[120] |
BERGREM HA, VALDERHAUG TG, HARTMANN A, et al. Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy[J]. Clin J Am Soc Nephrol, 2010, 5(4): 616-622. DOI: 10.2215/CJN.07501009.
|
[121] |
ISHIKAWA S, TASAKI M, IKEDA M, et al. Pretransplant BMI should be <25 in Japanese kidney transplant recipients: a single-center experience[J]. Transplant Proc, 2023, 55(1): 72-79. DOI: 10.1016/j.transproceed.2022.10.058.
|
[122] |
BAMBHA KM, DODGE JL, GRALLA J, et al. Low, rather than high, body mass index confers increased risk for post-liver transplant death and graft loss: risk modulated by model for end-stage liver disease[J]. Liver Transpl, 2015, 21(10): 1286-1294. DOI: 10.1002/lt.24188.
|
[123] |
KIM DG, KIM BS, CHOI HY, et al. Association between post-transplant uric acid level and renal allograft fibrosis: analysis using Banff pathologic scores from renal biopsies[J]. Sci Rep, 2018, 8(1): 11601. DOI: 10.1038/s41598-018-29948-9.
|
[124] |
KITTLESON MM, BEAD V, FRADLEY M, et al. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients[J]. J Heart Lung Transplant, 2007, 26(5): 498-503. DOI: 10.1016/j.healun.2007.01.039.
|
[125] |
BURROUGHS TE, SWINDLE J, TAKEMOTO S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients[J]. Transplantation, 2007, 83(8): 1027-1034. DOI: 10.1097/01.tp.0000259617.21741.95.
|